Amneal Pharmaceuticals, Inc. (AMRX)

USD 7.69

(-4.71%)

Revenue Summary of Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals, Inc.'s latest annual revenue in 2023 was 2.39 Billion USD , up 8.2% from previous year.
Amneal Pharmaceuticals, Inc.'s latest quarterly revenue in 2024 Q1 was 659.19 Million USD , up 6.84% from previous quarter.
Amneal Pharmaceuticals, Inc. reported a annual revenue of 2.21 Billion USD in annual revenue 2022, up 5.67% from previous year.
Amneal Pharmaceuticals, Inc. reported a annual revenue of 2.09 Billion USD in annual revenue 2021, up 5.08% from previous year.
Amneal Pharmaceuticals, Inc. reported a quarterly revenue of 701.78 Million USD for 2024 Q2, up 6.46% from previous quarter.
Amneal Pharmaceuticals, Inc. reported a quarterly revenue of 2.39 Billion USD for 2023 FY, up 8.2% from previous quarter.

Annual Revenue Chart of Amneal Pharmaceuticals, Inc. (2023 - 2014)

Historical Annual Revenue of Amneal Pharmaceuticals, Inc. (2023 - 2014)

Year	Revenue	Revenue Growth
2023	2.39 Billion USD	8.2%
2022	2.21 Billion USD	5.67%
2021	2.09 Billion USD	5.08%
2020	1.99 Billion USD	22.51%
2019	1.62 Billion USD	-2.2%
2018	1.66 Billion USD	60.88%
2017	1.03 Billion USD	1.52%
2016	1.01 Billion USD	17.54%
2015	866.28 Million USD	10.27%
2014	785.62 Million USD	0.0%

Year	Revenue	Revenue Growth
2024 Q1	659.19 Million USD	6.84%
2024 Q2	701.78 Million USD	6.46%
2023 FY	2.39 Billion USD	8.2%
2023 Q4	616.98 Million USD	-0.49%
2023 Q1	557.54 Million USD	-8.56%
2023 Q3	620.04 Million USD	3.5%
2023 Q2	599.04 Million USD	7.44%
2022 Q1	497.63 Million USD	-7.31%
2022 FY	2.21 Billion USD	5.67%
2022 Q4	609.75 Million USD	11.77%
2022 Q3	545.55 Million USD	-2.47%
2022 Q2	559.35 Million USD	12.4%
2021 Q3	528.59 Million USD	-1.21%
2021 Q4	536.89 Million USD	1.57%
2021 Q2	535.07 Million USD	8.51%
2021 Q1	493.1 Million USD	-3.32%
2021 FY	2.09 Billion USD	5.08%
2020 Q2	464.66 Million USD	-6.79%
2020 Q4	510.03 Million USD	-1.78%
2020 FY	1.99 Billion USD	22.51%
2020 Q3	519.29 Million USD	11.76%
2020 Q1	498.53 Million USD	25.47%
2019 Q2	404.64 Million USD	-9.3%
2019 Q4	397.32 Million USD	5.03%
2019 FY	1.62 Billion USD	-2.2%
2019 Q1	446.12 Million USD	-10.33%
2019 Q3	378.28 Million USD	-6.51%
2018 Q2	413.78 Million USD	50.36%
2018 FY	1.66 Billion USD	60.88%
2018 Q4	497.52 Million USD	4.42%
2018 Q3	476.48 Million USD	15.15%
2018 Q1	275.18 Million USD	-6.2%
2017 FY	1.03 Billion USD	1.52%
2017 Q1	225.68 Million USD	-24.41%
2017 Q2	259.87 Million USD	15.15%
2017 Q3	254.73 Million USD	-1.98%
2017 Q4	293.36 Million USD	15.17%
2016 Q4	298.57 Million USD	0.0%
2016 FY	1.01 Billion USD	17.54%
2015 FY	866.28 Million USD	10.27%
2014 FY	785.62 Million USD	0.0%

Peer Revenue Comparison of Amneal Pharmaceuticals, Inc.

Name	Revenue	Revenue Difference
Bausch Health Companies Inc.	8.75 Billion USD	72.666%
Catalent, Inc.	4.38 Billion USD	45.364%
Emergent BioSolutions Inc.	1.04 Billion USD	-128.115%
Elanco Animal Health Incorporated	4.41 Billion USD	45.809%
Perrigo Company plc	4.65 Billion USD	48.586%
Teva Pharmaceutical Industries Limited	15.84 Billion USD	84.895%
Zoetis Inc.	8.54 Billion USD	71.985%